leishmania

enzyme_104282

patenting

tuberculosis_115111

jama_112802

neglected tropical

shewhart

antiparasitic

noise figure

apostichopus

emotion_123347

trypanothione

ocps

cruzi_24330

thiols_91164

purinergic

Drug Discovery Today

Neglected tropical diseases (NTDs), which include leishmaniasis, Chagas disease, human African trypanosomiasis (HAT), and schistosomiasis, remain public health problems in developing countries, as highlighted in the 2021–2030 WHO Roadmap on NTDs. This agenda sets the challenges for the control and elimination of NTDs by 2030. Fortunately, NTD drug discovery has shifted from traditional to modern strategies combining medicinal chemistry, phenotypic and molecular assays, multiparameter optimization, structural biology, and omics approaches. Structure- and ligand-based drug design have fostered NTD drug discovery by enabling data-driven molecular optimization, expansion to previously inaccessible chemical spaces, and knowledge building from biological data. These efforts have integrated parasite biology and medicinal chemistry to advance drug discovery in this key area of global health.

Approaches to advance drug discovery for neglected tropical diseases